{"DataElement":{"publicId":"2677117","version":"1","preferredName":"Other Malignant Neoplasm Transplantation Time Recurrent Disease Chemosensitivity Type","preferredDefinition":"A description of the sensitivity to chemotherapy for the recurrent other malignancy at the time of transplantation.","longName":"O_CNCR_RL_CHMSNSV_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2677115","version":"1","preferredName":"Other Malignant Neoplasm Transplantation Time Recurrent Disease","preferredDefinition":"Not otherwise specified._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas._The grafting of tissues from one individual to another or place to place within a single individual._The continuum of experience in which events pass from the future through the present to the past._The return of a disease after a period of remission.","longName":"OTR_MLGNT_TRN_RLPS","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2660471","version":"1","preferredName":"Other Malignant Neoplasm","preferredDefinition":"Not otherwise specified.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004","longName":"C17649:C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"33E5C497-ED80-4C81-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2007-06-27","modifiedBy":"ONEDATA","dateModified":"2007-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2676463","version":"1","preferredName":"Transplantation Time Recurrent Disease","preferredDefinition":"The grafting of tissues from one individual to another or place to place within a single individual.:the continuum of experience in which events pass from the future through the present to the past.:the return of a sign, symptom, or disease after a remission.","longName":"C15342:C25207:C38155","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Time","conceptCode":"C25207","definition":"The continuum of experience in which events pass from the future through the present to the past.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Recurrent Disease","conceptCode":"C38155","definition":"The return of a disease after a period of remission.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3938A932-CA86-725A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-03","modifiedBy":"ONEDATA","dateModified":"2007-09-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39660F08-072C-0CDA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2486888","version":"1","preferredName":"Chemosensitivity Type","preferredDefinition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better._Something distinguishable as an identifiable class based on common qualities.","longName":"CHEM_SENS_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"9","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2565695","version":"1","preferredName":"Unknown","longName":"2565695","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-CDAC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-02-26","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-26","modifiedBy":"MMADDINENI","dateModified":"2024-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"395037C6-23BA-52BE-E044-0003BA3F9857","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"ALEYR","dateModified":"2007-09-04","deletedIndicator":"No"},{"value":"Untreated","valueDescription":"Without Therapeutic Procedure","ValueMeaning":{"publicId":"2676532","version":"1","preferredName":"Without Therapeutic Procedure","longName":"2676532","preferredDefinition":"Used to indicate the absence or lack of something or someone. (from Merriam-Webster OnLine): An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Without","conceptCode":"C25718","definition":"Used to indicate the absence or lack of something or someone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"395037C6-23C9-52BE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"395037C6-23E2-52BE-E044-0003BA3F9857","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"ALEYR","dateModified":"2007-09-04","deletedIndicator":"No"},{"value":"Resistant","valueDescription":"Resistance","ValueMeaning":{"publicId":"2674643","version":"1","preferredName":"Resistance","longName":"2674643","preferredDefinition":"Failure of a cancer to shrink after treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Resistance","conceptCode":"C19391","definition":"Failure of a cancer to shrink after treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"384C7304-8808-48E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-22","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"395037C6-23EE-52BE-E044-0003BA3F9857","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"ALEYR","dateModified":"2007-09-04","deletedIndicator":"No"},{"value":"Sensitive","valueDescription":"Sensitivity","ValueMeaning":{"publicId":"2676533","version":"1","preferredName":"Sensitivity","longName":"2676533","preferredDefinition":"A measure of the minimum change in an input signal that an instrument can detect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sensitivity","conceptCode":"C68816","definition":"A measure of the minimum change in an input signal that an instrument can detect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"395037C6-23FC-52BE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"395037C6-2415-52BE-E044-0003BA3F9857","beginDate":"2006-06-16","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-04","modifiedBy":"ALEYR","dateModified":"2007-09-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008570","version":"1","preferredName":"Personal attributes","preferredDefinition":"NCI Thesaurus code: CL003786: Personal Attribute\r\n","longName":"PERSONAL_ATTRIBUTES","context":"SPOREs","contextVersion":"2.31","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"B7FD1513-11B0-2714-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-03-03","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-03-03","modifiedBy":"SBREXT","dateModified":"2004-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2724589","version":"1","preferredName":"Chemosensitivity Type","preferredDefinition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.:Type; a subdivision of a particular kind of thing.","longName":"C71488:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemosensitivity","conceptCode":"C71488","definition":"Sensitivity of a malignancy to administration of chemotherapy, usually defined as the achievement of a partial response or better.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4455D875-2DF8-060D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-01-22","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-01-22","modifiedBy":"ONEDATA","dateModified":"2008-01-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"165D4F55-1DB3-1A89-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_omalig_sen_chemo","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedClinicalInterpretation:value","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"If there was a relapse of the","type":"Preferred Question Text","description":"If there was a relapse of the other malignancy, what was the sensitivity to chemotherapy?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping for CDE:2677117","type":"BRIDG Mapping Path","description":"PerformedObservation [assess sens.] > PerformedClinicalInterpretation.value(ANY=>CD) WHERE PerformedObservation [assess sens.] > DefinedObservation.nameCode = \"assess sensitivity to chemo\" AND PerformedObservation [assess sens.] > Subject > PerformedObservation [assess HL status] >  PerformedDiagnosis.value = {other malignancy} AND PerformedDiagnosis.diseaseStatusCode = \"relapse\" AND PerformedObservation [assess HL status] > DefinedObservation [assess HL status] > DefinedCompositionRelationship > DefinedProcedure [treatment of HL] > DefinedCompositionRelationship > DefinedProcedure [overall HCT process] > DefinedCompositionRelationship > DefinedProcedure [prep reg] > DefinedCompostionRelationship > DefinedObservation [assess sens.]","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"39661AB4-E292-0F09-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-05","modifiedBy":"KUMMEROA","dateModified":"2021-04-20","changeDescription":". .1/8/14mn-added Bridg info. 2021-4-20 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}